{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T05:54:44Z","timestamp":1793426084769,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T00:00:00Z","timestamp":1699488000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T00:00:00Z","timestamp":1699488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s10557-023-07522-4","type":"journal-article","created":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T03:23:21Z","timestamp":1699500201000},"page":"481-490","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Hyperoside Protects Trastuzumab-Induced Cardiotoxicity via Activating the PI3K\/Akt Signaling Pathway"],"prefix":"10.1007","volume":"39","author":[{"given":"Shanshan","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanjun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suifen","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sa","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bikui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0381-0242","authenticated-orcid":false,"given":"Jian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,9]]},"reference":[{"issue":"4905","key":"7522_CR1","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1126\/science.2470152","volume":"244","author":"DJ Slamon","year":"1989","unstructured":"Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244(4905):707\u201312.","journal-title":"Science"},{"issue":"14","key":"7522_CR2","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","volume":"365","author":"D Slamon","year":"2011","unstructured":"Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365(14):1273\u201383.","journal-title":"N Engl J Med"},{"issue":"16","key":"7522_CR3","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa052122","volume":"353","author":"EH Romond","year":"2005","unstructured":"Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673\u201384.","journal-title":"N Engl J Med"},{"issue":"11","key":"7522_CR4","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783\u201392.","journal-title":"N Engl J Med"},{"issue":"13","key":"7522_CR5","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1200\/JCO.20.01204","volume":"39","author":"M Piccart","year":"2021","unstructured":"Piccart M, Procter M, Fumagalli D, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer in the APHINITY Trial: 6 years' follow-up. J Clin Oncol. 2021;39(13):1448\u201357.","journal-title":"J Clin Oncol"},{"issue":"3","key":"7522_CR6","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/eci.12589","volume":"46","author":"GM Rosa","year":"2016","unstructured":"Rosa GM, Gigli L, Tagliasacchi MI, et al. Update on cardiotoxicity of anti-cancer treatments. Eur J Clin Invest. 2016;46(3):264\u201384.","journal-title":"Eur J Clin Invest"},{"issue":"22","key":"7522_CR7","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1016\/j.jacc.2019.03.495","volume":"73","author":"M Guglin","year":"2019","unstructured":"Guglin M, Krischer J, Tamura R, et al. Randomized trial of lisinopril versus carvedilol to prevent trastuzumab cardiotoxicity in patients with breast cancer. J Am Coll Cardiol. 2019;73(22):2859\u201368.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"7522_CR8","first-page":"Cd006243","volume":"2012","author":"L Moja","year":"2012","unstructured":"Moja L, Tagliabue L, Balduzzi S, et al. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev. 2012;2012(4):Cd006243.","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"7522_CR9","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s00395-016-0576-z","volume":"111","author":"Z Vermeulen","year":"2016","unstructured":"Vermeulen Z, Segers VF, De Keulenaer GW. ErbB2 signaling at the crossing between heart failure and cancer. Basic Res Cardiol. 2016;111(6):60.","journal-title":"Basic Res Cardiol"},{"issue":"1","key":"7522_CR10","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s11897-010-0003-y","volume":"7","author":"Z Jiang","year":"2010","unstructured":"Jiang Z, Zhou M. Neuregulin signaling and heart failure. Curr Heart Fail Rep. 2010;7(1):42\u20137.","journal-title":"Curr Heart Fail Rep"},{"issue":"Suppl 1","key":"7522_CR11","first-page":"1","volume":"10","author":"CE Rupert","year":"2015","unstructured":"Rupert CE, Coulombe KL. The roles of neuregulin-1 in cardiac development, homeostasis, and disease. Biomark Insights. 2015;10(Suppl 1):1\u20139.","journal-title":"Biomark Insights"},{"issue":"8","key":"7522_CR12","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1007\/s00018-019-03340-w","volume":"77","author":"K Leemasawat","year":"2020","unstructured":"Leemasawat K, Phrommintikul A, Chattipakorn SC, Chattipakorn N. Mechanisms and potential interventions associated with the cardiotoxicity of ErbB2-targeted drugs: insights from in vitro, in vivo, and clinical studies in breast cancer patients. Cell Mol Life Sci. 2020;77(8):1571\u201389.","journal-title":"Cell Mol Life Sci"},{"key":"7522_CR13","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ahj.2017.03.010","volume":"188","author":"M Guglin","year":"2017","unstructured":"Guglin M, Munster P, Fink A, Krischer J. Lisinopril or Coreg CR in reducing cardiotoxicity in women with breast cancer receiving trastuzumab: a rationale and design of a randomized clinical trial. Am Heart J. 2017;188:87\u201392.","journal-title":"Am Heart J"},{"key":"7522_CR14","doi-asserted-by":"publisher","first-page":"8866660","DOI":"10.1155\/2022\/8866660","volume":"2022","author":"G Liu","year":"2022","unstructured":"Liu G, Zhang J, Sun F, Ma J, Qi X. Ginsenoside Rg2 Attenuated Trastuzumab-Induced Cardiotoxicity in Rats. Biomed Res Int. 2022;2022:8866660.","journal-title":"Biomed Res Int"},{"key":"7522_CR15","doi-asserted-by":"publisher","unstructured":"Li G, Zhu F, Wei P, et al. Metabolic Engineering of Escherichia coli for Hyperoside Biosynthesis. Microorganisms. 2022;10(3). https:\/\/doi.org\/10.3390\/microorganisms10030628.","DOI":"10.3390\/microorganisms10030628"},{"key":"7522_CR16","doi-asserted-by":"publisher","unstructured":"He S, Yin X, Wu F, et al. Hyperoside protects cardiomyocytes against hypoxia-induced injury via upregulation of microRNA-138. Mol Med Rep. 2021;23(4). https:\/\/doi.org\/10.3892\/mmr.2021.11925.","DOI":"10.3892\/mmr.2021.11925"},{"key":"7522_CR17","doi-asserted-by":"publisher","first-page":"114187","DOI":"10.1016\/j.jep.2021.114187","volume":"276","author":"Y Yang","year":"2021","unstructured":"Yang Y, Li J, Rao T, Fang Z, Zhang J. The role and mechanism of hyperoside against myocardial infarction in mice by regulating autophagy via NLRP1 inflammation pathway. J Ethnopharmacol. 2021;276:114187.","journal-title":"J Ethnopharmacol"},{"key":"7522_CR18","doi-asserted-by":"publisher","first-page":"108545","DOI":"10.1016\/j.intimp.2022.108545","volume":"105","author":"S Wei","year":"2022","unstructured":"Wei S, Xiao Z, Huang J, et al. Disulfiram inhibits oxidative stress and NLRP3 inflammasome activation to prevent LPS-induced cardiac injury. Int Immunopharmacol. 2022;105:108545.","journal-title":"Int Immunopharmacol"},{"issue":"6","key":"7522_CR19","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1093\/cvr\/cvaa324","volume":"117","author":"NG Frangogiannis","year":"2021","unstructured":"Frangogiannis NG. Cardiac fibrosis. Cardiovasc Res. 2021;117(6):1450\u201388.","journal-title":"Cardiovasc Res"},{"issue":"7","key":"7522_CR20","doi-asserted-by":"publisher","first-page":"5061","DOI":"10.1128\/MCB.19.7.5061","volume":"19","author":"M Andjelkovi\u0107","year":"1999","unstructured":"Andjelkovi\u0107 M, Maira SM, Cron P, Parker PJ, Hemmings BA. Domain swapping used to investigate the mechanism of protein kinase B regulation by 3-phosphoinositide-dependent protein kinase 1 and Ser473 kinase. Mol Cell Biol. 1999;19(7):5061\u201372.","journal-title":"Mol Cell Biol"},{"issue":"8","key":"7522_CR21","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/j.jcmg.2018.06.004","volume":"11","author":"JH Jordan","year":"2018","unstructured":"Jordan JH, Todd RM, Vasu S, Hundley WG. Cardiovascular magnetic resonance in the oncology patient. JACC Cardiovasc Imaging. 2018;11(8):1150\u201372.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"5","key":"7522_CR22","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1200\/JCO.2002.20.5.1215","volume":"20","author":"A Seidman","year":"2002","unstructured":"Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20(5):1215\u201321.","journal-title":"J Clin Oncol"},{"issue":"8","key":"7522_CR23","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1200\/JCO.2015.65.7916","volume":"35","author":"D Zardavas","year":"2017","unstructured":"Zardavas D, Suter TM, Van Veldhuisen DJ, et al. Role of troponins I and T and N-terminal prohormone of brain natriuretic peptide in monitoring cardiac safety of patients with early-stage human epidermal growth factor receptor 2-positive breast cancer receiving trastuzumab: a herceptin adjuvant study cardiac marker substudy. J Clin Oncol. 2017;35(8):878\u201384.","journal-title":"J Clin Oncol"},{"issue":"10","key":"7522_CR24","doi-asserted-by":"publisher","first-page":"3490","DOI":"10.1158\/1078-0432.CCR-10-1359","volume":"17","author":"PG Morris","year":"2011","unstructured":"Morris PG, Chen C, Steingart R, et al. Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib. Clin Cancer Res. 2011;17(10):3490\u20139.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"7522_CR25","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1373\/clinchem.2015.241232","volume":"61","author":"M Putt","year":"2015","unstructured":"Putt M, Hahn VS, Januzzi JL, et al. Longitudinal changes in multiple biomarkers are associated with cardiotoxicity in breast cancer patients treated with doxorubicin, taxanes, and trastuzumab. Clin Chem. 2015;61(9):1164\u201372.","journal-title":"Clin Chem"},{"issue":"19","key":"7522_CR26","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1042\/CS20200230","volume":"134","author":"A Geissler","year":"2020","unstructured":"Geissler A, Ryzhov S, Sawyer DB. Neuregulins: protective and reparative growth factors in multiple forms of cardiovascular disease. Clin Sci (Lond). 2020;134(19):2623\u201343.","journal-title":"Clin Sci (Lond)"},{"issue":"8","key":"7522_CR27","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1161\/CIRCULATIONAHA.107.690487","volume":"116","author":"K Lemmens","year":"2007","unstructured":"Lemmens K, Doggen K, De Keulenaer GW. Role of neuregulin-1\/ErbB signaling in cardiovascular physiology and disease: implications for therapy of heart failure. Circulation. 2007;116(8):954\u201360.","journal-title":"Circulation"},{"issue":"2","key":"7522_CR28","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/s41556-018-0261-6","volume":"21","author":"J Guo","year":"2019","unstructured":"Guo J, Dai X, Laurent B, et al. AKT methylation by SETDB1 promotes AKT kinase activity and oncogenic functions. Nat Cell Biol. 2019;21(2):226\u201337.","journal-title":"Nat Cell Biol"},{"issue":"7","key":"7522_CR29","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1002\/ptr.7478","volume":"36","author":"Q Wang","year":"2022","unstructured":"Wang Q, Wei HC, Zhou SJ, et al. Hyperoside: A review on its sources, biological activities, and molecular mechanisms. Phytother Res. 2022;36(7):2779\u2013802.","journal-title":"Phytother Res"},{"key":"7522_CR30","doi-asserted-by":"publisher","unstructured":"Charachit N, Sukhamwang A, Dejkriengkraikul P, Yodkeeree S. Hyperoside and quercitrin in houttuynia cordata extract attenuate UVB-induced human keratinocyte cell damage and oxidative stress via modulation of MAPKs and Akt signaling pathway. Antioxidants (Basel). 2022;11(2). https:\/\/doi.org\/10.3390\/antiox11020221.","DOI":"10.3390\/antiox11020221"},{"issue":"4","key":"7522_CR31","doi-asserted-by":"publisher","first-page":"8657","DOI":"10.1080\/21655979.2022.2054499","volume":"13","author":"S Fan","year":"2022","unstructured":"Fan S, Pan H, Huang J, Lei Z, Liu J. Hyperoside exerts osteoprotective effect on dexamethasone-induced osteoblasts by targeting NADPH Oxidase 4 (NOX4) to inhibit the reactive oxygen species (ROS) accumulation and activate c-Jun N-terminal kinase (JNK) pathway. Bioengineered. 2022;13(4):8657\u201366.","journal-title":"Bioengineered"},{"key":"7522_CR32","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.3389\/fphar.2020.01065","volume":"11","author":"H Xing","year":"2020","unstructured":"Xing H, Fu R, Cheng C, et al. Hyperoside protected against oxidative stress-induced liver injury via the PHLPP2-AKT-GSK-3\u03b2 signaling pathway in vivo and in vitro. Front Pharmacol. 2020;11:1065.","journal-title":"Front Pharmacol"},{"issue":"11","key":"7522_CR33","doi-asserted-by":"publisher","first-page":"e79543","DOI":"10.1371\/journal.pone.0079543","volume":"8","author":"MK ElZarrad","year":"2013","unstructured":"ElZarrad MK, Mukhopadhyay P, Mohan N, et al. Trastuzumab alters the expression of genes essential for cardiac function and induces ultrastructural changes of cardiomyocytes in mice. PLoS One. 2013;8(11):e79543.","journal-title":"PLoS One"},{"issue":"4","key":"7522_CR34","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1074\/jbc.M804570200","volume":"284","author":"LI Gordon","year":"2009","unstructured":"Gordon LI, Burke MA, Singh AT, et al. Blockade of the erbB2 receptor induces cardiomyocyte death through mitochondrial and reactive oxygen species-dependent pathways. J Biol Chem. 2009;284(4):2080\u20137.","journal-title":"J Biol Chem"},{"key":"7522_CR35","doi-asserted-by":"publisher","first-page":"828061","DOI":"10.3389\/fphar.2022.828061","volume":"13","author":"X Wang","year":"2022","unstructured":"Wang X, Li W, Zhang Y, et al. Calycosin as a novel PI3K activator reduces inflammation and fibrosis in heart failure through AKT-IKK\/STAT3 axis. Front Pharmacol. 2022;13:828061.","journal-title":"Front Pharmacol"},{"issue":"2","key":"7522_CR36","doi-asserted-by":"publisher","first-page":"e22150","DOI":"10.1096\/fj.202101428RR","volume":"36","author":"M Shiraishi","year":"2022","unstructured":"Shiraishi M, Yamaguchi A, Suzuki K. Nrg1\/ErbB signaling-mediated regulation of fibrosis after myocardial infarction. Faseb j. 2022;36(2):e22150.","journal-title":"Faseb j."},{"key":"7522_CR37","doi-asserted-by":"publisher","first-page":"13","DOI":"10.4137\/BCBCR.S32791","volume":"10","author":"J Zambrano","year":"2016","unstructured":"Zambrano J, Yeh ES. Autophagy and apoptotic crosstalk: mechanism of therapeutic resistance in HER2-positive breast cancer. Breast Cancer (Auckl). 2016;10:13\u201323.","journal-title":"Breast Cancer (Auckl)"},{"issue":"6","key":"7522_CR38","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1158\/1535-7163.MCT-15-0741","volume":"15","author":"N Mohan","year":"2016","unstructured":"Mohan N, Shen Y, Endo Y, ElZarrad MK, Wu WJ. Trastuzumab, but not pertuzumab, dysregulates HER2 signaling to mediate inhibition of autophagy and increase in reactive oxygen species production in human cardiomyocytes. Mol Cancer Ther. 2016;15(6):1321\u201331.","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"7522_CR39","doi-asserted-by":"publisher","first-page":"105283","DOI":"10.1016\/j.isci.2022.105283","volume":"25","author":"S Xie","year":"2022","unstructured":"Xie S, Yang Y, Luo Z, et al. Role of non-cardiomyocytes in anticancer drug-induced cardiotoxicity: a systematic review. iScience. 2022;25(11):105283.","journal-title":"iScience"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-023-07522-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-023-07522-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-023-07522-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T05:21:53Z","timestamp":1748323313000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-023-07522-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,9]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["7522"],"URL":"https:\/\/doi.org\/10.1007\/s10557-023-07522-4","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,9]]},"assertion":[{"value":"25 October 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experiments were conducted according to the National Institutes of Health Guide (NIH publications \u2116 8023) for the Care and Use of Laboratory Animals, and approved by the Medicine Animal Welfare Committee of Xiangya School of Medicine (SYXK-2020\/0019).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declared that there is no conflict of interest associated with this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}